Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Durlobactam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innoviva’s ZEVTERA, XACDURO Nominated for 2025 Prix Galien
    Innoviva’s ZEVTERA, XACDURO Nominated for 2025 Prix Galien

    13 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250813478127/en/Innoviva-Specialty-Therapeutics-Antimicrobial-Therapies-ZEVTERA-and-XACDURO-Nominated-for-the-2025-Prix-Galien-USA-Best-Pharmaceutical-Product-Award

    BUSINESSWIRE
    13 Aug 2025
    Share Share
    Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug
    Zai Lab & Pfizer Announce Collaboration on Antibacterial Drug

    21 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241121825806/en

    BUSINESSWIRE
    21 Nov 2024
    Share Share
    Zai Lab, Innoviva's SUL-DUR Approved In China For Pneumonia
    Zai Lab, Innoviva's SUL-DUR Approved In China For Pneumonia

    20 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240519020622/en

    BUSINESSWIRE
    20 May 2024
    Share Share
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO

    23 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230523005961/en

    BUSINESSWIRE
    23 May 2023
    Share Share
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases

    11 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230511005905/en

    BUSINESSWIRE
    11 May 2023
    Share Share
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections

    18 Apr 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-innovivas-drug-multidrug-resistant-bacterial-infections-2023-04-17/

    REUTERS
    18 Apr 2023
    Share Share